Trial intelligence / Profile preview

Zanubrutinib plus Obinutuzumab as First-Line Therapy in Older Mantle Cell Lymphoma

ChiCTR2300071433Phase 2Recruiting

Sponsor

First Affiliated Hospital, Zhejiang University School of Medicine

Start

Jun 2023

Modality

Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Countries

1